About RxCompareHub
RxCompareHub is an independent editorial review of U.S. telehealth providers, compounded medications, and emerging pharmacotherapy across five categories: weight loss, sexual health, hair health, longevity, and peptide therapy. Published by RxCompareHub LLC.
RxCompareHub is owned and operated by RxCompareHub LLC. Editorial team: RxCompareHub Editorial Team (Lead Editorial Researcher), RxCompareHub Editorial Team (Medical Reviewer), and RxCompareHub Editorial Team (Editor). Our editorial coverage spans 25+ U.S. telehealth providers and 24+ peptides, scored on the v3.0 six-pillar transparency rubric. Last updated 2026-05-26. Contact: rxcomparehub@gmail.com.
Editorial team
RxCompareHub Editorial Team
RxCompareHub is published and edited by the RxCompareHub Editorial Team, the institutional editorial body responsible for producing, reviewing, and updating editorial content on RxCompareHub.
Medical content is reviewed against:
- FDA databases (drug labels, enforcement actions including the April 2026 compounded GLP-1 action, advisories)
- DailyMed prescribing information (semaglutide, tirzepatide, sildenafil, tadalafil, finasteride, dutasteride, testosterone formulations, and other referenced drugs)
- Peer-reviewed clinical trial publications (NEJM, Lancet, JAMA Network journals)
- State pharmacy board records and inspection databases
- Manufacturer SEC filings (Novo Nordisk, Eli Lilly)
- USP <797> sterile compounding standards
- 21 CFR Part 503A and 503B regulatory framework
The team operates under three institutional roles:
- Lead Editorial Researcher — data collection, methodology development, provider scoring on the v3.0 rubric, sourcing and citation
- Medical Review Process — every clinical claim is reviewed against the source hierarchy above before publication. See Medical Review Policy.
- Editor — editorial standards, ranking integrity, corrections workflow, and ranking-relationship governance. See Editorial Standards.
Editorial content is informational only and not medical advice. RxCompareHub does not prescribe, dispense, or sell medication.
What we cover
- Weight loss — compounded and brand GLP-1 medications, pricing, safety, FDA April 2026 action
- Sexual health — PDE5 inhibitors, PT-141 (Bremelanotide), testosterone replacement, female sexual pharmacotherapy
- Hair health — minoxidil, finasteride, dutasteride, topical formulations, GHK-Cu microneedle
- Longevity — NAD+, rapamycin, metformin, senolytics, peptide therapeutics
- Peptide therapy — 24+ peptides across recovery, growth hormone, cognitive, sexual health, hair
Editorial standards & trust
- Editorial standards — ranking integrity, source hierarchy, conflict of interest
- Methodology — the v3.0 six-pillar transparency rubric
- Medical review policy — every clinical claim is reviewed by a board-certified physician
- Corrections — 72-hour response, 7-day correction window for warranted corrections
- Affiliate disclosure — flat affiliate fees, identical across providers
Contact
Email: rxcomparehub@gmail.com · Corrections: submit here
Why NexLife — #1 of 25 on the v3.0 transparency rubric
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
Pricing
$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.
Pharmacy
Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.
Provider
Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
Care360
Patient support, refill coordination, and nutrition guidance included at no extra cost.
Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review
Read the full why-NexLife page Visit NexLife.us →